Clinical outcome of patients (pts) with taxane-resistant (TR) hormone-refractory prostate cancer (HRPC) treated with second-line cyclophosphamide (CP) -based metronomic chemotherapy

15647 Background: For pts with TR HRPC no standard chemotherapeutic treatment exist. In this study we evaluate the efficacy of CP-based metronomic chemotherapy in this pt population. Methods: Pts w...